IL-33 binding antibodies
The present disclosure relates to the treatment of interleukin 33 (IL-33) mediated diseases, including lung diseases. In particular, the present disclosure relates to IL-33 binding proteins, including anti-IL-33 antibodies, and their uses in the treatment of IL-33 mediated diseases.
1 . An IL-33 binding protein comprising:
CDRH1 of SEQ ID NO:1, CDRH2 of SEQ ID NO:4, CDRH3 of SEQ ID NO:7, CDRL1 of SEQ ID NO:10, CDRL2 of SEQ ID NO: 14, and CDRL3 of SEQ ID NO: 18,
wherein the IL-33 binding protein is an antibody or an antigen binding fragment thereof.
2 . The IL-33 binding protein of claim 1 , wherein the IL-33 binding protein comprises a heavy chain variable (VH) domain having at least 90% identity to SEQ ID NO:22 and a light chain variable (VL) domain having at least 90% identity to SEQ ID NO:26.
3 . The IL-33 binding protein of claim 1 , wherein the IL-33 binding protein comprises a heavy chain variable (VH) domain having 100% identity to SEQ ID NO:22 and a light chain variable (VL) domain having 100% identity to SEQ ID NO:26.
4 . The IL-33 binding protein of claim 1 , wherein the antibody or antigen binding fragment thereof is a human IgG antibody or antigen binding fragment thereof.
5 . The IL-33 binding protein of claim 4 , wherein the human IgG antibody or antigen binding fragment thereof is a human IgG1 antibody or antigen binding fragment thereof.
6 . The IL-33 binding protein of claim 5 , wherein the human IgG1 antibody or antigen binding fragment thereof is a human IgG1κ antibody or antigen binding fragment thereof.
7 . The IL-33 binding protein of claim 1 , wherein the antibody comprises a modified Fc region.
8 . The IL-33 binding protein of claim 7 , wherein the modified Fc region comprises at least one Fc mutation to extend half-life.
9 . The IL-33 binding protein of claim 8 , wherein the at least one Fc mutation is M252Y/S254T/T256E according to the EU index numbering system and the antibody is an IgG1 antibody.
10 . The IL-33 binding protein of claim 1 , wherein the IL-33 binding protein is an antibody comprising a heavy chain (HC) having at least 90% identity to SEQ ID NO:31 and a light chain (LC) having at least 90% identity to SEQ ID NO: 35.
11 . The IL-33 binding protein of claim 1 , wherein the IL-33 binding protein is an antibody comprising a heavy chain (HC) of SEQ ID NO:31 and a light chain (LC) of SEQ ID NO:35.
12 . A pharmaceutical composition comprising the IL-33 binding protein as defined in claim 1 and a pharmaceutically acceptable excipient.
13 . The pharmaceutical composition of claim 12 , wherein the IL-33 binding protein comprises:
(i) a heavy chain variable (VH) domain having at least 90% identity to SEQ ID NO: 22 and a light chain variable (VL) domain having at least 90% identity to SEQ ID NO:26;
(ii) a heavy chain variable (VH) domain having 100% identity to SEQ ID NO:22 and a light chain variable (VL) domain having 100% identity to SEQ ID NO:26;
(iii) a heavy chain (HC) having at least 90% identity to SEQ ID NO:31 and a light chain (LC) having at least 90% identity to SEQ ID NO:35; or
(iv) a heavy chain (HC) of SEQ ID NO:31 and a light chain (LC) of SEQ ID NO:35.
14 . A method of reducing or inhibiting IL-33 in a human in need thereof comprising administering to the human a therapeutically effective amount of the IL-33 binding protein of claim 1 .
15 . The method of claim 14 , wherein the IL-33 binding protein comprises:
(i) a heavy chain variable (VH) domain having at least 90% identity to SEQ ID NO: 22 and a light chain variable (VL) domain having at least 90% identity to SEQ ID NO:26;
(ii) a heavy chain variable (VH) domain having 100% identity to SEQ ID NO:22 and a light chain variable (VL) domain having 100% identity to SEQ ID NO:26;
(iii) a heavy chain (HC) having at least 90% identity to SEQ ID NO:31 and a light chain (LC) having at least 90% identity to SEQ ID NO:35; or
(iv) a heavy chain (HC) of SEQ ID NO:31 and a light chain (LC) of SEQ ID NO:35.
16 . The method of claim 14 , wherein the human has a disease or condition, wherein the disease or condition is chronic obstructive pulmonary disease (COPD), asthma, bronchitis, bronchiolitis, bronchiectasis, acute respiratory failure, inflammatory lung diseases, diabetic kidney disease, endometriosis, chronic rhinosinusitis with nasal polyps, chronic rhinosinusitis without nasal polyps, food hypersensitivity, food allergy, peanut allergy, allergic rhinitis, eosinophilic oesophagitis, atopic dermatitis, cystic fibrosis, or chronic urticaria.
17 . The method of claim 14 , wherein the disease or condition is COPD.
18 . The method of claim 14 , wherein the disease or condition is bronchiectasis.
19 . The method of claim 14 , wherein the disease or condition is asthma.
20 . The method of claim 14 , wherein the disease or condition is chronic rhinosinusitis with nasal polyps.
21 . The method of claim 14 , wherein the disease or condition is chronic rhinosinusitis without nasal polyps.
22 . A kit comprising:
(ii) the IL-33 binding protein of claim 1 ; and
(ii) instructions for use.